TWI583385B - 使用tor之激酶抑制劑之癌症治療 - Google Patents

使用tor之激酶抑制劑之癌症治療 Download PDF

Info

Publication number
TWI583385B
TWI583385B TW102109160A TW102109160A TWI583385B TW I583385 B TWI583385 B TW I583385B TW 102109160 A TW102109160 A TW 102109160A TW 102109160 A TW102109160 A TW 102109160A TW I583385 B TWI583385 B TW I583385B
Authority
TW
Taiwan
Prior art keywords
substituted
pyrazine
unsubstituted
methyl
tor kinase
Prior art date
Application number
TW102109160A
Other languages
English (en)
Chinese (zh)
Other versions
TW201343168A (zh
Inventor
徐水禪
克利斯坦 梅耶 黑格
海瑟 雷蒙
莉麗 羅蘭安 王
Original Assignee
標誌製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 標誌製藥公司 filed Critical 標誌製藥公司
Publication of TW201343168A publication Critical patent/TW201343168A/zh
Application granted granted Critical
Publication of TWI583385B publication Critical patent/TWI583385B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102109160A 2012-03-15 2013-03-14 使用tor之激酶抑制劑之癌症治療 TWI583385B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18

Publications (2)

Publication Number Publication Date
TW201343168A TW201343168A (zh) 2013-11-01
TWI583385B true TWI583385B (zh) 2017-05-21

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102109160A TWI583385B (zh) 2012-03-15 2013-03-14 使用tor之激酶抑制劑之癌症治療

Country Status (21)

Country Link
US (1) US20130245026A1 (https=)
EP (1) EP2825170B1 (https=)
JP (3) JP2015510891A (https=)
KR (3) KR20200070416A (https=)
CN (2) CN104519885A (https=)
AU (1) AU2013203153B2 (https=)
BR (1) BR112014022703A2 (https=)
CA (1) CA2866872A1 (https=)
EA (1) EA028414B1 (https=)
ES (1) ES2677874T3 (https=)
IL (1) IL234602B (https=)
MX (1) MX360878B (https=)
MY (1) MY174022A (https=)
NI (1) NI201400111A (https=)
NZ (1) NZ628416A (https=)
PH (1) PH12014502029B1 (https=)
SG (1) SG11201405707XA (https=)
TW (1) TWI583385B (https=)
UA (1) UA114315C2 (https=)
WO (1) WO2013138557A1 (https=)
ZA (1) ZA201406706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
TW201526894A (zh) * 2013-04-17 2015-07-16 Signal Pharm Llc 藉二氫吡并吡治療癌症
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666624C (en) 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
MX337906B (es) * 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US20110200556A1 (en) * 2008-08-20 2011-08-18 The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi Chemoprevention of head and neck squamous cell carcinomas
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
BR112014022703A2 (pt) * 2012-03-15 2021-05-04 Signal Pharmaceuticals, Llc método para o tratamento de carcinoma de células escamosas de cabeça e de pescoço, método para melhorar os critérios de avaliação, método para inibição da fosforilação, método para inibição de dna, método para a medição da inibição da fosforilação, kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bryan T. Hennessy et al., Exploiting the PI3K/AKT pathway for cancer drug discovery, Nature reviews Drug Discovery, 2005, Vol.4, 988-1004 *

Also Published As

Publication number Publication date
UA114315C2 (uk) 2017-05-25
KR102122617B1 (ko) 2020-06-12
CN104519885A (zh) 2015-04-15
CA2866872A1 (en) 2013-09-19
BR112014022703A2 (pt) 2021-05-04
IL234602A0 (en) 2014-11-30
JP2015510891A (ja) 2015-04-13
WO2013138557A1 (en) 2013-09-19
MY174022A (en) 2020-03-04
KR20140138927A (ko) 2014-12-04
KR20210071101A (ko) 2021-06-15
SG11201405707XA (en) 2014-10-30
EP2825170A1 (en) 2015-01-21
PH12014502029A1 (en) 2014-11-24
ES2677874T3 (es) 2018-08-07
JP2021102637A (ja) 2021-07-15
NZ628416A (en) 2016-04-29
ZA201406706B (en) 2016-05-25
US20130245026A1 (en) 2013-09-19
EA028414B1 (ru) 2017-11-30
JP2019108368A (ja) 2019-07-04
MX360878B (es) 2018-11-21
EA201491699A1 (ru) 2015-02-27
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
HK1201750A1 (en) 2015-09-11
MX2014011077A (es) 2014-10-14
NI201400111A (es) 2015-01-15
EP2825170B1 (en) 2018-05-09
AU2013203153B2 (en) 2015-09-03
IL234602B (en) 2020-05-31
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
TW201343168A (zh) 2013-11-01

Similar Documents

Publication Publication Date Title
TWI583385B (zh) 使用tor之激酶抑制劑之癌症治療
TWI600428B (zh) 使用tor激酶抑制劑之癌症治療
TWI622395B (zh) 使用tor之激酶抑制劑之癌症治療
TWI635862B (zh) 使用tor激酶抑制劑之癌症治療
TWI578989B (zh) 以lkb1突變之鑑定作為對tor激酶抑制劑敏感的預測性生物標記
TW201733585A (zh) 以tor激酶抑制劑治療癌症
AU2015213400B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015201138B2 (en) Treatment of cancer with TOR kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors